Zhenyu Xu Sells 4,000 Shares of SOPHiA GENETICS (NASDAQ:SOPH) Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) insider Zhenyu Xu sold 4,000 shares of the business’s stock in a transaction that occurred on Monday, July 13th. The stock was sold at an average price of $5.70, for a total transaction of $22,800.00. Following the sale, the insider owned 610,887 shares of the company’s stock, valued at approximately $3,482,055.90. This represents a 0.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Zhenyu Xu also recently made the following trade(s):

• On Monday, July 6th, Zhenyu Xu sold 7,393 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.17, for a total transaction of $38,221.81.
• On Monday, April 20th, Zhenyu Xu sold 608 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.21, for a total transaction of $3,167.68.

SOPHiA GENETICS Stock Up 1.6%

Shares of NASDAQ SOPH opened at $5.77 on Thursday. The stock has a fifty day moving average price of $5.21 and a 200 day moving average price of $5.01. The company has a current ratio of 2.06, a quick ratio of 1.90 and a debt-to-equity ratio of 1.05. SOPHiA GENETICS SA has a 12-month low of $2.92 and a 12-month high of $6.30. The company has a market cap of $484.05 million, a P/E ratio of -11.10 and a beta of 0.96.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its earnings results on Tuesday, May 5th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.04). SOPHiA GENETICS had a negative return on equity of 62.74% and a negative net margin of 44.48%.The company had revenue of $21.69 million during the quarter, compared to analysts’ expectations of $20.40 million.

Analyst Ratings Changes

A number of research analysts have recently commented on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Tuesday, April 21st. BTIG Research reaffirmed a “buy” rating and set a $8.00 price target on shares of SOPHiA GENETICS in a report on Monday, June 15th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, SOPHiA GENETICS currently has a consensus rating of “Hold” and an average price target of $7.50.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in SOPH. Hennion & Walsh Asset Management Inc. acquired a new position in SOPHiA GENETICS during the 2nd quarter worth $567,000. Royal Bank of Canada raised its stake in shares of SOPHiA GENETICS by 3,130.2% in the 1st quarter. Royal Bank of Canada now owns 19,381 shares of the company’s stock valued at $96,000 after purchasing an additional 18,781 shares in the last quarter. Sei Investments Co. bought a new position in shares of SOPHiA GENETICS during the first quarter worth about $1,772,000. Principal Financial Group Inc. lifted its position in shares of SOPHiA GENETICS by 0.7% during the first quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock worth $6,976,000 after purchasing an additional 9,800 shares during the last quarter. Finally, Hodges Capital Management Inc. acquired a new position in SOPHiA GENETICS in the first quarter worth about $2,157,000. 31.59% of the stock is currently owned by institutional investors.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.